Blood Cell Development and Cancer Keystone, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Blood. 2012 Nov 1;120(18):3764-73. doi: 10.1182/blood-2012-03-415349. Epub 2012 Sep 13.
Ribosomal protein (RP) mutations in diseases such as 5q- syndrome both disrupt hematopoiesis and increase the risk of developing hematologic malignancy. However, the mechanism by which RP mutations increase cancer risk has remained an important unanswered question. We show here that monoallelic, germline inactivation of the ribosomal protein L22 (Rpl22) predisposes T-lineage progenitors to transformation. Indeed, RPL22 was found to be inactivated in ∼ 10% of human T-acute lymphoblastic leukemias. Moreover, monoallelic loss of Rpl22 accelerates development of thymic lymphoma in both a mouse model of T-cell malignancy and in acute transformation assays in vitro. We show that Rpl22 inactivation enhances transformation potential through induction of the stemness factor, Lin28B. Our finding that Rpl22 inactivation promotes transformation by inducing expression of Lin28B provides the first insight into the mechanistic basis by which mutations in Rpl22, and perhaps some other RP genes, increases cancer risk.
核糖体蛋白(RP)突变与疾病相关,例如 5q- 综合征,这既破坏了造血功能,又增加了患血液恶性肿瘤的风险。然而,RP 突变增加癌症风险的机制仍然是一个重要的未解决的问题。我们在这里表明,核糖体蛋白 L22(Rpl22)的单等位基因、种系失活使 T 系祖细胞易于转化。事实上,约 10%的人类 T 急性淋巴细胞白血病中发现 RPL22 失活。此外,Rpl22 的单等位基因缺失加速了 T 细胞恶性肿瘤的小鼠模型和体外急性转化试验中胸腺淋巴瘤的发展。我们表明,Rpl22 的失活通过诱导干性因子 Lin28B 增强转化潜能。我们的发现表明,Rpl22 失活通过诱导 Lin28B 的表达促进转化,这为 Rpl22 突变以及可能的其他 RP 基因增加癌症风险的机制提供了第一个见解。